7月30日 - ** 制药公司Alnylam Pharmaceuticals(ALNY.O)的股价在盘前交易中下跌21.5%,至225.00美元
** 该公司将2026年产品总净收入预期从此前预估的49亿至53亿美元下调至47亿至51亿美元
** 第二季度销售额为1.29亿美元,低于分析师预期的1.32亿美元——据伦敦证券交易所集团(LSEG)数据
** 报告显示第二季度调整后每股收益为1.84美元,高于1.55美元的预期
** 截至上一交易日收盘,该股年内累计跌幅达27.9%
7月30日 - ** 制药公司Alnylam Pharmaceuticals(ALNY.O)的股价在盘前交易中下跌21.5%,至225.00美元
** 该公司将2026年产品总净收入预期从此前预估的49亿至53亿美元下调至47亿至51亿美元
** 第二季度销售额为1.29亿美元,低于分析师预期的1.32亿美元——据伦敦证券交易所集团(LSEG)数据
** 报告显示第二季度调整后每股收益为1.84美元,高于1.55美元的预期
** 截至上一交易日收盘,该股年内累计跌幅达27.9%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.